References
- Plum S. M., Holaday J. H., Ruiz A., Madsen J. W., Fogler W. E., Fortier A. H. Administration of a liposomal FGF‐2 peptide vaccine leads to abrogation of FGF‐2‐mediated angiogenesis and tumor development. Vaccine 2001; 19(9–10)1294–1303, [CSA]
- Abulafia O., Sherer D. M. Angiogenesis in the ovary. Am. J. Obstet. Gynecol. 2000; 182(1)240–246, [PUBMED], [INFOTRIEVE], [CSA]
- Fujimoto J., Sakaguchi H., Hirose R., Wen H., Tamaya T. Angiogenesis in endometriosis and angiogenic factors. Gynecol. Obstet. Investig. 1999; 48(1)14–20, [CROSSREF], [CSA]
- Smith M. F., McIntush E. W., Smith G. W. Mechanisms associated with corpus luteum development. J. Anim. Sci. 1994; 72(7)1857–1872, [PUBMED], [INFOTRIEVE]
- Wang D. I., Gotlieb A. I. Fibroblast growth factor 2 enhances early stages of in vitro endothelial repair by microfilament bundle reorganization and cell elongation. Exp. Mol. Pathol. 1999; 66(3)179–190, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Menetrey J., Kasemkijwattana C., Day C. S., Bosch P., Vogt M., Fu F. H., Moreland M. S., Huard J. Growth factors improve muscle healing in vivo. J. Bone Jt. Surg., Br. 2000; 82(1)131–137, [CROSSREF], [CSA]
- Raballo R., Rhee J., Lyn‐Cook R., Leckman J. F., Scwartz M. L., Vaccarino F. M. Basic fibroblast growth factor (Fgf2) is necessary for cell proliferation and neurogenesis in the developing cerebral cortex. J. Neurosci. 2000; 20(13)5012–5023, [PUBMED], [INFOTRIEVE]
- Leconte I., Fox J. C., Baldwin H. S., Buck C. A., Swain J. L. Adenoviral‐mediated expression of antisense RNA to fibroblast growth factors disrupt murine vascular development. Dev. Dyn. 1998; 213(4)421–430, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Ortega S., Ittmann M., Tsang S. H., Ehrlich M., Basilico C. Neuronal defects and delayed wound healing in mice lacking fibroblast growth factor 2. Proc. Natl. Acad. Sci. U. S. A. 1998; 95(10)5672–5677, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- White W. I., Cassatt D. R., Madsen J., Burke S. J., Woods R. M., Wassef N. M., Alving C. R. Antibody and cytotoxic T‐lymphocyte responses to a single liposome‐associated peptide antigen. Vaccine 1995; 13(12)1111–1122, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Frey A., Mantis N., Kozlowski P. A., Quayle A. J., Bajardi A., Perdomo J. J., Robey F. A., Neutra M. R. Immunization of mice with peptomers covalently coupled to aluminum oxide particles. Vaccine 1999; 17(23–24)3007–3019, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Pougatcheva S. O., Abernathy E. S., Vzorov A. N., Compans R. W., Frey T. K. Development of a rubella virus DNA vaccine. Vaccine 1999; 17(15–16)2104–2112, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Anacker R. L., Ribi E., Tarmina D. F., Fadness L., Mann R. E. Relationship of footpad sensitivity to purified protein derivatives and resistance to airborne infection with Mycobacterium tuberculosis of mice vaccinated with mycobacterial cell walls. J. Bacteriol. 1969; 100(1)51–57, [PUBMED], [INFOTRIEVE]
- Bloch W., Huggel K., Sasaki T., Grose R., Bugnon P., Addicks K., Timpl R., Werner S. The angiogenesis inhibitor endostatin impairs blood vessel maturation during wound healing. FASEB J. 2000; 14(15)2373–2376, [PUBMED], [INFOTRIEVE], [CSA]
- Alving C. R., Koulchin V., Glenn G. M., Rao M. Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunol. Rev. 1995; 145: 5–31, [PUBMED], [INFOTRIEVE], [CSA]
- Hoffman S. L., Sedegah M., Hedstrom R. C. Protection against malaria by immunization with a Plasmodium yoelii circumsporozite protein nucleic acid vaccine. Vaccine 1994; 12(16)1529–1533, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Pye D., Vandeberg K. L., Dyer S. L., Irving D. O., Goss N. H., Woodrow G. C., Saul A., Alving C. R., Richards R. L., Ballou W. R., Wu M. J., Skoff K., Anders R. F. Selection of an adjuvant for vaccination with the malaria antigen, MSA‐2. Vaccine 1997; 15(9)1017–1023, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
- Niethammer A. G., Xiang R., Becker J. C., Wodrich H., Pert U., Karsten G., Eliceriri B. P., Reisfeld R. A. DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat. Med. 2002; 8(12)1369–1375, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]